Disclosure Of Entity's Operating Segments [Text Block]

Innate Pharma - Filing #2811003

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Disclosure of entity's operating segments [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of operating segments [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue	—	61 641 EUR	—	—	—	—	—	—	—	—	—	—	57 674 EUR	—	—	—	—	—
Tax expense (income)	—	— EUR	—	—	—	—	—	—	—	—	—	—	— EUR	—	—	—	—	—
Profit (loss) before tax	—	7 570 EUR	—	—	—	—	—	—	—	—	—	—	57 972 EUR	—	—	—	—	—
Profit (loss) from continuing operations	—	7 570 EUR	—	—	—	—	—	—	—	—	—	—	57 972 EUR	—	—	—	—	—
Profit (loss)	— EUR	7 570 EUR	—	— EUR	7 570 EUR	— EUR	— EUR	— EUR	— EUR	—	— EUR	— EUR	58 103 EUR	— EUR	— EUR	58 103 EUR	— EUR	— EUR
Assets	—	—	184 193 EUR	—	—	—	—	—	—	207 863 EUR	—	—	—	—	—	—	—	—
Cash flows from (used in) operating activities	—	32 558 EUR	—	—	—	—	—	—	—	—	—	—	19 155 EUR	—	—	—	—	—
Cash flows from (used in) investing activities	—	20 631 EUR	—	—	—	—	—	—	—	—	—	—	1 877 EUR	—	—	—	—	—
Cash flows from (used in) financing activities	—	1 966 EUR	—	—	—	—	—	—	—	—	—	—	1 828 EUR	—	—	—	—	—
Disclosure of products and services [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of major customers [abstract]
Disclosure of major customers [line items]